Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1

Interventions

pembrolizumab 10Filgrastim 7Ifosfamide 4Carboplatin 4aldesleukin 3Temozolomide 3Peripheral Blood Stem Cell Transplantation 3Drug Therapy 3Docetaxel 3Cyclophosphamide 3Counseling 3fludarabine phosphate 2fludarabine 2etoposide phosphate 2cemiplimab 2belinostat 2atezolizumab 2Thiotepa 2Surveys and Questionnaires 2Radiotherapy 2Nivolumab 2Methods 2Metformin 2Early Intervention, Educational 2Doxorubicin 2Bupropion 2Blood Specimen Collection 2Amifostine 23-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 2valspodar 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × Technetium Tc 99m Sestamibi × Gynecologic × Clear all
NCT00069160 2012-10-12

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
48 enrolled 13 charts
GenitourinaryGynecologicThoracic

Uterine Cervical Neoplasms, Kidney Neoplasms, Lung Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡